Get Advances in ophthalmology and optometry myron yanoff (ed.) free all chapters by Education Libraries

https://ebookmass.com/product/advances-inophthalmology-and-optometry-myron-yanoff-ed/

Download more ebook from https://ebookmass.com

More products digital (pdf, epub, mobi) instant download maybe you interests ...

Advances in Ophthalmology and Optometry, 2022 (Volume 7-1) (Advances, Volume 7-1) Myron Yanoff Md (Editor)

https://ebookmass.com/product/advances-in-ophthalmology-andoptometry-2022-volume-7-1-advances-volume-7-1-myron-yanoff-mdeditor/

Advances in Ophthalmology and Optometry, 2021 (Volume 6-1) (Advances, Volume 6-1) Myron Yanoff Md (Editor)

https://ebookmass.com/product/advances-in-ophthalmology-andoptometry-2021-volume-6-1-advances-volume-6-1-myron-yanoff-mdeditor/

Ophthalmology 5th Edition Myron Yanoff (Lead Editor)

https://ebookmass.com/product/ophthalmology-5th-edition-myronyanoff-lead-editor/

Business Aspects of Optometry 3rd Edition

https://ebookmass.com/product/business-aspects-of-optometry-3rdedition/

Ocular Pathology 8th Edition

M.D. Yanoff

https://ebookmass.com/product/ocular-pathology-8th-edition-m-dyanoff/

Ophthalmology 5th Edition

https://ebookmass.com/product/ophthalmology-5th-edition/

Advances in Food and Nutrition Research Fidel Toldra

https://ebookmass.com/product/advances-in-food-and-nutritionresearch-fidel-toldra/

Advances in Food and Nutrition Research 1st Edition Fidel Toldrá

https://ebookmass.com/product/advances-in-food-and-nutritionresearch-1st-edition-fidel-toldra/

Recent Advances in Micro- and Macroalgal Processing

Gaurav Rajauria

https://ebookmass.com/product/recent-advances-in-micro-andmacroalgal-processing-gaurav-rajauria/

ADVANCES IN Ophthalmology and Optometry

Editor-in-Chief

Myron Yanoff, MD

Chair Emeritus, Department of Ophthalmology, Drexel University, Adjunct Professor, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania

ADVANCESIN OphthalmologyandOptometry

DavidA.Crandall

Optometry

OpticalCoherenceTechnologyinGlaucomaDiagnosis JosephSowka,JessicaSteen,andGregCaldwell

Introduction1

Opticalcoherencetomographyretinalnerveﬁberlayeranalysisin glaucomadiagnosis2

Opticalcoherencetomographymacularanalysisinglaucomadiagnosis4

Opticalcoherencetomographyangiographyinglaucomadiagnosis7

Clinicscarepoints10 Disclosure10

AnUpdateonNeurodegenerativeDiseaseforEyeCare Providers

KellyA.Malloy,ErinM.Draper,AshleyKayMaglione, TinaZeng,andElizabethMarunde

Introduction:neurodegenerativediseaseandtheeye13

Neurodegenerativediseasedeﬁnition13

Variedpathophysiologyofneurodegenerativediseases14

Prevalentvisualandocularassociationsofneurodegenerativedisease14

Roleofeyecareprovidersinneurodegenerativedisease16

Visualandocularassociationsofneurodegenerativedisease16

Eyelidfunctioninneurodegenerativedisease16

Anteriorsegmentﬁndingsinneurodegenerativedisease20

Posteriorsegmentﬁndingsinneurodegenerativedisease21

Afferentvisualfunctioninneurodegenerativedisease22

Efferentvisualfunctioninneurodegenerativedisease24

Hallucinationsinneurodegenerativedisease25

Visualandocularsideeffectsofneurodegenerativediseasetreatments27

Adversesequela28

Associatedimprovementinneurodegenerativediseasemanifestations28

Futureavenues:neurodegenerativedisease,theeye,andthevisualsystem28

Expectedincreaseinprevalenceofneurodegenerativedisease28

Optimalbiomarkersinvolveeyesandvision31

Summary:neurodegenerativedisease,theeye,andthevisualsystem31

Eyecareprovidersasscreenersofneurodegenerativedisease31

Earlyidentiﬁcationandneurologyreferraliskey31

Eyecareprovidershelpimprovequalityoflifeofpatientswith neurodegenerativedisease32

Expectedsurgeofresearchintoneurodegenerativedisease34

Clinicscarepoints34

Disclosure34

NeuroanatomicalStructuresinExtraocularMusclesand TheirPotentialImplicationintheManagementof Strabismus

JanRichardBruenech

Introduction39

Structureandfunctionofhumanextraocularmuscles40

Sensoryreceptorsinhumanextraocularmuscles41

Musclespindles41

Tendonreceptors41

Theroleofproprioceptioninoculomotorcontrol43

Theneuralpathwayforproprioception43

Theneuralsubstrateforthecontrolofeyemovements44

Binocularvisionanomalies45

Currentconceptsinthediagnosisandmanagementofstrabismus46

Nonsurgicalmanagementofstrabismus46

Opticalcorrections46

Neuromuscularstimulationthroughexercise47

Surgicalmanagementofstrabismus48

Summaryanddiscussion49

Summary51

Disclosure51

Clinicscarepoints51

Pediatric

PrenatalDiagnosisofRetinoblastoma

KelseyChen,LuisF.Goncalves,and AparnaRamasubramanian

Introduction55 Incidence56 Riskfactors56

CurrentManagementofPediatricGlaucoma

SushmitaKaushik,DeepikaDhingra,andSurinderS.Pandav

SystemicImmunomodulatoryTherapyinPediatric Uveitis

IlariaMaccora,EthanS.Sen,andAthimalaipetV.Ramanan

IremKoc¸,HayyamKiratli,andBhavnaChawla

Classiﬁcationofseeding104

Impactofintravitrealinjectionsonpatientmanagement105

Usesofintravitrealchemotherapyotherthanforvitreousseeds107

Dosage107

Pharmacokineticsofintravitrealmelphalan112

Useofintravitrealtopotecan113

Pharmacokineticsofintravitrealtopotecan113

Stabilityofmelphalanandtopotecan114

Futureavenues115

Summary115

Clinicscarepoints116

OphthalmicPathology&OcularOncology

ApplicationsofPlaqueBrachytherapyinPosterior SegmentTumors:AClinicalReview

PuneetJain,PaulT.Finger,andBhavnaChawla

Introduction119

Historicalperspective120

Choroidalhemangioma121 Managementofchoroidalhemangioma122

Managementofdiffusechoroidalhemangioma122

Retinalcapillaryhemangioma124

Vasoproliferativeretinaltumors125

Retinoblastoma126

Choroidalmelanoma127

Limitationsofplaquebrachytherapy129

Futureavenues129

Methodsfordosede-escalation129

Clinicscarepoints130

IntraocularTumors—AdvancesinOphthalmicPathology

SnehaGiridhar,DipankarDas,andJyotirmayBiswas

Retinoblastoma133

Pathology134

MolecularPathology138 Uvealmelanoma138

Pathology140 Genetics141

Primaryvitreoretinallymphoma142

Cytologyandimmunohistochemistry142 Molecularfeatures144

Summary145

Clinicscarepoints145

Acknowledgments145 Disclosure146

AdenoidCysticCarcinomaoftheLacrimalGland

NurKhatib,IoanaCatalinaIonescu,DanielBriscoe,and PeeroozSaeed

Introduction147

Signiﬁcance(in-depthanalysis)148 Signsandsymptoms148 Staging148 Histopathology148 Imaging150 Treatmentapproach150 Futureavenues155 Summary155 Clinicscarepoints156

Cataract&RefractiveSurgery

Micro-InvasiveGlaucomaSurgery

DavidA.CrandallandCandiceYousif

Introduction159

Signiﬁcanceandcurrentrelevance160

IStenttrabecularmicro-bypassstent162

Hydrusmicrostent163

Goniotomy-assistedtrabeculotomy165 Trab360trabeculotomy166 Trabectome167 Kahookdualblade167 Abinternocanaloplasty168 Visco360andOMNI169 XENgelstent169 Preserﬂo170 Summary170 Clinicscarepoints171 Disclosure172 VitreoretinalDisease

Backgroundandintroduction175 Overviewofartiﬁcialintelligence176 Evaluatingdeeplearningalgorithms178 Diabeticretinopathy179 Age-relatedmaculardegeneration181 Future182 Summary183 Clinicscarepoints184 Disclosure184

RetinaintheAgeofCOVID-19

SamuelGelnick,MaribAkanda,andRonniLieberman

Background187

Introduction188

Generalcleaningandhygiene188

Personalprotectiveequipment188

Pandemicrestrictions189

Careinanactivepandemic189

Schedulingvisits189

Precautionsforprocedures192

Intravitrealinjections192

Precautionsforlaserprocedures193

Schedulingfollow-upvisits193

PatientswithpositivescreeningortestingforCOVID-19194

Careafterimmediatepandemicrestrictionsarelifted195

Continuedscreeningandschedulingprecautions195

Dayofappointmentprecautions195

Performingelectivesurgery196

Operatingroomprecautions197

Summary197

Clinicscarepoints198 Disclosure198

DiagnosticandTreatmentUpdateonSickleCell Retinopathy

CesarAlfaro,EthanK.Sobol,andRobinGinsburg

Introduction201

Classiﬁcationsystem205 Diagnosis206

Opticalcoherencetomography207

Opticalcoherencetomographyangiography207

Ultra-wideﬂuoresceinangiography209 Management210

Anti-vascularendothelialgrowthfactor211

Glaucoma

GlaucomaSurgery:WhichSurgerytoPickforYour Patient?

RabeaKassemandPaulHarasymowycz

Introduction218

Signiﬁcance218

Subconjunctivalsurgery219

Whennottooptforsubconjunctivalsurgery?219 Nonpenetratingglaucomasurgery219

Trabeculectomy222

XENGelImplant(AllerganInc,Irvine,CA,USA)222

PreserﬂoMicroshunt(SantenPharmaceuticalCoLtd,Osaka, Japan)223

Tubeshunts223

Cyclodestructiveprocedures224

Schlemmcanal–basedprocedures225 Selectivelasertrabeculoplasty225

Schlemmcanal-basedmicroinvasiveglaucomasurgery226

Suprachoroidal231

CyPass(Alcon,FortWorth,TX,USA)231

Specialconsiderations231

Patientswithveryadvanceddisease231

Patientswithveryhighintraocularpressure232

Patientswithangle-closureglaucoma232 Primaryangleclosure233 Primaryangle-closureglaucoma233

Patientswithneovascularglaucoma234 Reoperationafterfailedglaucomasurgery234 Currentrelevanceandfutureavenues236 Summary239 Clinicscarepoints241 Disclosure241

OcularBloodFlowasItRelatestoRaceandDiseaseon Glaucoma

BrentSiesky,AlonHarris,AliceC.VerticchioVercellin, GiovannaGuidoboni,andJamesC.Tsai Introduction245 Signiﬁcance246

Racialdisparitiesinglaucoma248 Mechanismsbehindracialdisparitiesinglaucoma248 Summary258

Clinicalcarepoints259 Funding259 Financialdisclosures259

Neuro-ophthalmology

GlaucomaasaNeurodegenerativeDisease:AClinician Perspective

NoelC.Y.ChanandJaneW.Chan Introduction263

Isglaucomaaneurodegenerativedisease?264

Sickeyecomeswithasickbrain264

Commonclinicalcharacteristicsbetweenglaucomaand neurodegenerativedisease266

Overlappingpathophysiologybetweenglaucomaandother neurodegenerativedisease267

Neuroinﬂammation267

Oxidativestressandmitochondrialdysfunction267

Dysregulationofcalciumdependentprocess268

Alterationsofautophagymachinery268

Misfoldingofproteins268

Activationofglia269

Glaucomaandcerebrospinalﬂuid269 Lookingintothefuture269

Neuro-OphthalmologicManifestationsofNovel Coronavirus

DevinBetschandPaulR.Freund Introduction275

CorneaandExternalDiseases

AdvancesinEndothelialKeratoplastySurgery

ArielChen,DanielChoi,andMichaelE.SulewskiJr. Introduction289

Signiﬁcance290

Lamellarkeratoplasty290

Descemetstrippingendothelialkeratoplasty293

Descemet’smembraneendothelialkeratoplasty295

Descemetorhexiswithoutendothelialkeratoplasty298 Relevanceandfutureavenues298

UpdateintheManagementofKeratoconus

EnnyOyeniranandZujajaTauqeer

Introduction307

Cornealcross-linking310

Spectaclesandcontactlenses313 Scleralcontactlenses315

Intrastromalcornealringsegments317

Penetratingkeratoplasty319

Deepanteriorlamellarkeratoplasty320 Summary320 Clinicscarepoints321 Disclosure321

UpdateonRefractiveSurgery

TianyuLiu,BrianM.Shafer,andVanceThompson

Introduction325

Signiﬁcanceandin-depthanalysisofthetopic326

Cornealrefractivesurgery326

Intraocularrefractivesurgery328

Treatmentofpresbyopia330

Currentrelevanceandfutureavenuestoinvestigatethetopic332 Managementofhigher-orderaberrations:wavefront-optimized, wavefront-guided,andtopography-guidedlaserablation332 Advancesinrefractivelenticulesurgery333 Accommodativeintraocularlens334 Summary336

Oculoplastics

XanthelasmaPalpebrarum:AnOculoplasticViewpointof OptimalTreatment

LironPe’erandArieY.Nemet

RefractiveErrorChangesAssociatedwithEyelidWeight Placement

CatN.BurkatandSusanLuo

Introduction358

Signiﬁcance359

Efﬁcacyofuppereyelidweightplacement359 Causesoflagophthalmos360 Operativetechnique360 Complicationsofuppereyelidloading360 Refractiveerrorchanges360 Relevanceandfutureavenues367 Transitiontoplatinum368 Costofplatinumversusgold368 Futureavenues369

Summary369 Clinicscarepoints370 Acknowledgments371 Disclosure371

RefractiveChangeafterUpperEyelidSurgery

ChintanA.Pathak,NenitaMaganti,andCatN.Burkat

Introduction373 Preoperativechanges375 Postoperativechanges376 Clinicalrelevance377 Clinicscarepoints377 Acknowledgments378

CanalicularStenosisSecondarytoChemotherapeutic Agents

NenitaMaganti,ChintanA.Pathak,andCatN.Burkat

Introduction379

Chemotherapeuticagentsknowntocausecanalicularstenosis380 5-Fluorouracil380 Mitomycin-C381 Docetaxel381

Signiﬁcanceofepiphorasecondarytocanalicularabnormality382 Managementofcanalicularstenosis382 Summary386 Clinicscarepoints386 Acknowledgments387

Uveitis

OpticalCoherenceTomographyAngiographyinWhiteDot Syndromes

KarlN.Becker,AngelineC.Rivkin,andPoojaV.Bhat

Introduction391

Overview392

Cross-sectionalandenfacevisualizationsoftheposteriorcirculation393

Birdshotchorioretinopathy394

Multipleevanescentwhitedotsyndrome395

Punctateinnerchoroiditis396

Serpiginouschoroiditis397

Acuteposteriormultifocalplacoidpigmentepitheliopathy398

Acutezonaloccultouterretinopathy399

Multifocalchoroiditis400

Relevanceandfutureavenues400

Summary401

Clinicscarepoints401

ADVANCESIN OphthalmologyandOptometry

Editor-in-Chief

MYRONYANOFF,MD,ChairEmeritus,DepartmentofOphthalmology,DrexelUniversity,AdjunctProfessor,DepartmentofOphthalmology,UniversityofPennsylvania,Philadelphia,Pennsylvania

SectionEditors

BHAVNACHAWLA,MD –OphthalmicPathology&OcularOncology

RPCenterforOphthalmicSciences,AllIndiaInstituteof MedicalSciences,NewDelhi,India

DAVIDA.CRANDALL,MD –Cataract&RefractiveSurgery

GlaucomaFellowshipDirector,HenryFordHealthSystem,Detroit,Michigan UniversityofUtah,SaltLakeCity,WayneStateUniversity,SaltLakeCity,Utah

PAULB.FREEMAN,OD,FAAO,FCOVD –Optometry

Diplomate,LowVision,Pittsburgh,Pennsylvania,ClinicalProfessor,Rosenberg SchoolofOptometry,UniversityoftheIncarnate,Word,SanAntonio,Texas

MORRISE.HARTSTEIN,MD,FACS –Oculoplastics

Director,OphthalmicPlasticandReconstructiveSurgery,Ophthalmology,Shamir MedicalCenter,Zeriﬁn,Israel;TelAvivUniversity,SacklerSchoolofMedicine, TelAviv,Israel

RUSTUMKARANJIA,MD,PhD,FRCSC,DABO –Neuro-ophthalmology

DepartmentofOphthalmology,DavidGeffenSchoolofMedicineat UCLA,LosAngeles,California;DohenyEyeInstitute,LosAngeles, California,DohenyEyeInstitute,LosAngeles,California,DepartmentofOphthalmology,UniversityofOttawa,Ottawa,Ontario,Canada,OttawaHospital ResearchInstitute,TheOttawaHospital,Ottawa,Ontario,Canada

RONNIM.LIEBERMAN,MD –VitreoretinalDisease

AssistantProfessorofOphthalmology,IcahnSchoolofMedicineatMt.Sinai, QueensHospitalCenter,Jamaica,NewYork

ANN-MARIELOBO,MD –Uveitis

Co-Director,UveitisService,AssistantProfessor,Departmentof OphthalmologyandVisualSciences,IllinoisEyeandEarInﬁrmary, UniversityofIllinoisatChicago,Chicago,Ilinois

STEPHENORLIN,MD –CorneaandExternalDiseases

AssociateProfessor,ScheieEyeInstitute,UniversityofPennsylvania,Perelman SchoolofMedicine,Philadelphia,Pennsylvania

JOSEPHM.ORTIZ,MD,FRCOphth –Glaucoma

ConsultantinOphthalmology,SacredHeartHospital,Allentown, Pennsylvania;ConsultantinOphthalmology,AbingtonMemorialHospital, Abington,Pennsylvania;FormerlyAssistantProfessorofOphthalmology, HahnemannUniversityHospital,DrexelUniversitySchoolofMedicine, Philadelphia,Pennsylvania

LEONARDJ.PRESS,OD,FAAO,FCOVD –Optometry

PressConsulting,P.C.,Lakewood,NewJersey;AdjunctProfessor,Southern CollegeofOptometry,Memphis,Tennessee

APARNARAMASUBRAMANIAN,MD –PediatricOphthalmology

DirectorofRetinoblasmaandOcularOncology,PhoenixChildren’sHospital, Phoenix,Arizona

Director,ContinuityPublishing:DoloresMeloni

Editor:LaurenBoyle

DevelopmentalEditor:JessicaCanaberal

2021ElsevierInc.Allrightsreserved.

Thisperiodicalandtheindividualcontributionscontainedinitareprotectedundercopyrightby Elsevierandthefollowingtermsandconditionsapplytotheiruse:

Photocopying

Singlephotocopiesofsinglearticlesmaybemadeforpersonaluseasallowedbynationalcopyright laws.PermissionofthePublisherandpaymentofafeeisrequiredforallotherphotocopying, includingmultipleorsystematiccopying,copyingforadvertisingorpromotionalpurposes, resale,andallformsofdocumentdelivery.Specialratesareavailableforeducationalinstitutions thatwishtomakephotocopiesfornon-proﬁteducationalclassroomuse. Forinformationonhowtoseekpermissionvisit www.elsevier.com/permissions orcall:(+44)1865 843830(UK)/(+1)2152393804(USA).

DerivativeWorks

Subscribersmayreproducetablesofcontentsorpreparelistsofarticlesincludingabstractsfor internalcirculationwithintheirinstitutions.PermissionofthePublisherisrequiredforresaleor distributionoutsidetheinstitution.PermissionofthePublisherisrequiredforallother derivativeworks,includingcompilationsandtranslations(pleaseconsult www.elsevier.com/ permissions).

ElectronicStorageorUsage

PermissionofthePublisherisrequiredtostoreoruseelectronicallyanymaterialcontainedinthis periodical,includinganyarticleorpartofanarticle(pleaseconsult www.elsevier.com/permissions). Exceptasoutlinedabove,nopartofthispublicationmaybereproduced,storedinaretrieval systemortransmittedinanyformorbyanymeans,electronic,mechanical,photocopying, recordingorotherwise,withoutpriorwrittenpermissionofthePublisher.

Notice

NoresponsibilityisassumedbythePublisherforanyinjuryand/ordamagetopersonsorproperty asamatterofproductsliability,negligenceorotherwise,orfromanyuseoroperationofany methods,products,instructionsorideascontainedinthematerialherein.Becauseofrapid advancesinthemedicalsciences,inparticular,independentveriﬁcationofdiagnosesanddrug dosagesshouldbemade.

Althoughalladvertisingmaterialisexpectedtoconformtoethical(medical)standards,inclusionin thispublicationdoesnotconstituteaguaranteeorendorsementofthequalityorvalueofsuch productoroftheclaimsmadeofitbyitsmanufacturer.

Reprints: Forcopiesof100ormoreofarticlesinthispublication,pleasecontacttheCommercial ReprintsDepartment,ElsevierInc.,360ParkAvenueSouth,NewYork,NY10010-1710.Tel: 212-633-3874;Fax:212-633-3820;E-mail: reprints@elsevier.com PrintedintheUnitedStatesofAmerica.

EditorialOfﬁce: Elsevier 1600JohnF.KennedyBlvd, Suite1800 Philadelphia,PA19103-2899

InternationalStandardSerialNumber:2452-1760

InternationalStandardBookNumber:13:978-0-323-81377-8

Another random document with no related content on Scribd:

Section 4. Information about Donations to the Project Gutenberg Literary Archive Foundation

Project Gutenberg™ depends upon and cannot survive without widespread public support and donations to carry out its mission of increasing the number of public domain and licensed works that can be freely distributed in machine-readable form accessible by the widest array of equipment including outdated equipment. Many small donations ($1 to $5,000) are particularly important to maintaining tax exempt status with the IRS.

The Foundation is committed to complying with the laws regulating charities and charitable donations in all 50 states of the United States. Compliance requirements are not uniform and it takes a considerable effort, much paperwork and many fees to meet and keep up with these requirements. We do not solicit donations in locations where we have not received written confirmation of compliance. To SEND DONATIONS or determine the status of compliance for any particular state visit www.gutenberg.org/donate.

While we cannot and do not solicit contributions from states where we have not met the solicitation requirements, we know of no prohibition against accepting unsolicited donations from donors in such states who approach us with offers to donate.

International donations are gratefully accepted, but we cannot make any statements concerning tax treatment of donations received from outside the United States. U.S. laws alone swamp our small staff.

Please check the Project Gutenberg web pages for current donation methods and addresses. Donations are accepted in a number of other ways including checks, online payments and

credit card donations. To donate, please visit: www.gutenberg.org/donate.

Section 5. General Information About Project Gutenberg™ electronic works

Professor Michael S. Hart was the originator of the Project Gutenberg™ concept of a library of electronic works that could be freely shared with anyone. For forty years, he produced and distributed Project Gutenberg™ eBooks with only a loose network of volunteer support.

Project Gutenberg™ eBooks are often created from several printed editions, all of which are confirmed as not protected by copyright in the U.S. unless a copyright notice is included. Thus, we do not necessarily keep eBooks in compliance with any particular paper edition.

Most people start at our website which has the main PG search facility: www.gutenberg.org.

This website includes information about Project Gutenberg™, including how to make donations to the Project Gutenberg Literary Archive Foundation, how to help produce our new eBooks, and how to subscribe to our email newsletter to hear about new eBooks.